Dr Richard Lipscombe, Managing Director of Proteomics International (ASX: PIQ), recently had an interview with AusBiz. The discussion centred around our announcement [ASX: 22 Nov 2023] on the US Centers for Medicare & Medicaid Services (CMS) confirming the reimbursement price for PromarkerD, predictive test for diabetic kidney disease at US$390.75 in the United States.
Watch the 5-minute interview here.
